09:33 AM EST - Cardiol Therapeutics Inc. : Announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association. The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. Cardiol Therapeutics Inc.
shares T.CRDL are trading unchanged at $1.50.
